VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
This is a 2-part, first-in-human dose-ranging study to evaluate the safety, tolerability and
pharmacokinetics of escalating doses of VNRX-5133 administered via intravenous (IV) infusion
in healthy subjects. In part 1, subjects will receive a single dose of VNRX-5133; in part 2
subjects will receive VNRX-5133 for 7 days.
Phase:
Phase 1
Details
Lead Sponsor:
Venatorx Pharmaceuticals, Inc.
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)